Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension

Shots: BI has launched Semintra (4mg/mL) in the EU for the treatment of systemic hypertension in cats Semintra has shown clinical efficacy in reducing proteinuria & blood pressure, which may help restore kidney balance while also promoting cat’s appetite, activity levels, & QoL Semintra (QD) is a telmisartan solution administered orally or on top…

ByRidhi RastogiFebruary 13, 2025

NEWS

Boehringer Ingelheim Reports Topline Data from P-III (FIBRONEER-ILD) Study of Nerandomilast for Progressive Pulmonary Fibrosis (PPF)

Shots: BI reported topline data from P-III (FIBRONEER-ILD) study assessing nerandomilast (BI 1015550; 9/18mg, BID) vs PBO in PPF pts (n=1178) for ~52wks. with regulatory filings in the US & other regions underway Study met its 1EP of absolute change from baseline in forced vital capacity (FVC; mL) with favorable safety consistent with P-II; full…

ByRidhi RastogiFebruary 11, 2025

NEWS

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

Shots: BI has entered into an agreement with Synaffix (Lonza’s company) to license the latter’s ADC technology, boosting its oncology pipeline via NBE Therapeutics (BI’s subsidiary) As per the terms, BI will access Synaffix’s platform for a specified but undisclosed number of targets, with the first target nominated & others to follow within a…

BySenior EditorJanuary 10, 2025

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2024

Shots: The third quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Eli Lilly's acquisition of Morphic Holdings for ~$3.2B This quarter also showcased multiple clinical trial results including Roche's P-I Study Data of CT-996 to treat Obesity Our…

BySaurabh ChaubeyOctober 1, 2024

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2024

Shots: The second quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Vertex’ acquisition of Alpine Immune Sciences for ~$4.9B This quarter also showcased multiple clinical trial results including Moderna’s P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19…

BySenior EditorJuly 2, 2024

NEWS

Boehringer Ingelheim Partners with Quallent Pharmaceuticals to Expand the Access of Cyltezo (Biosimilar, Humira)

Shots: Boehringer Ingelheim has signed an agreement with Quallent Pharmaceuticals to expand the access of citrate-free adalimumab-adbm, a biosimilar to Humira (adalimumab), across the US As per the agreement, BI will handle the manufacturing activity of adalimumab-adbm for Quallent and will continue the commercialization of Cyltezo (adalimumab-adbm) injection and Adalimumab-adbm Quallent will provide high-concentration (40mg/0.4mL)…

ByRidhi RastogiMay 13, 2024

INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Shots: Witness the journey of the biopharma companies over 20 years with this informative and engaging report. The report highlights the development of the biopharma industry and the key factors influencing them In 2023, JNJ reclaims the topmost position in the list from Pfizer with a revenue of $85.16B, showcasing a sharp 10.30 percent vs…

BySaurabh ChaubeyMay 1, 2024

NEWS

The US FDA Approves High Concentration of Boehringer Ingelheim’s Cyltezo (Biosimilar, Humira)

Shots: Boehringer Ingelheim has received the US FDA’s approval for the high-concentration (100mg/mL), citrate-free formulation of Cyltezo (biosimilar to Humira) to treat various chronic inflammatory diseases. Its low concentration of 50mg/mL has been available since Jul 2023 The approval was supported partly by the data from P-I (VOLTAIRE-HCLF) evaluating the bioavailability of high-concentration vs low-concentration…

ByDipanshu DixitMay 1, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Shots: The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industry In December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis PharmaShots has compiled a list of a…

BySaurabh ChaubeyJanuary 23, 2024

EXCLUSIVE

Noelle Bush in an Enlightening Interview with PharmaShots Shares Insights from the It Takes 2 Awareness Program

Shots: Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…

BySaurabh ChaubeyJanuary 15, 2024

Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension

Boehringer Ingelheim Reports Topline Data from P-III (FIBRONEER-ILD) Study of Nerandomilast for Progressive Pulmonary Fibrosis (PPF)

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

PharmaShots’ Key Highlights of Third Quarter 2024

PharmaShots’ Key Highlights of Second Quarter 2024

Boehringer Ingelheim Partners with Quallent Pharmaceuticals to Expand the Access of Cyltezo (Biosimilar, Humira)

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

The US FDA Approves High Concentration of Boehringer Ingelheim’s Cyltezo (Biosimilar, Humira)

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Noelle Bush in an Enlightening Interview with PharmaShots Shares Insights from the It Takes 2 Awareness Program

Contact US

FOLLOW US